Patrick McCall - 27 Apr 2025 Form 4 Insider Report for IN8BIO, INC. (INAB)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Jason Minio, Attorney-in-Fact
Issuer symbol: INAB
Transactions as of: 27 Apr 2025
Net transactions value: +$2,766
Form type: 4
Filing time: 07 May 2025, 20:45:09 UTC
Previous filing: 07 Feb 2025
Next filing: 23 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
McCall Patrick	CHIEF FINANCIAL OFFICER	C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK	/s/ Jason Minio, Attorney-in-Fact	07 May 2025	0001874384

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INAB	Common Stock	Options Exercise	$2,766	+15,000	+29%	$0.1844	67,071	30 Apr 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INAB	Series A Warrants (right to buy)	Disposed to Issuer		-15,000	-73%		5,492	27 Apr 2025	Common Stock	15,000	$0.4500	Direct	F1, F2, F3
transaction	INAB	Series A Warrants (right to buy)	Award		+15,000			15,000	27 Apr 2025	Common Stock	15,000	$0.1844	Direct	F1, F2
transaction	INAB	Series A Warrants (right to buy)	Options Exercise	$0	-15,000	-100%	$0.000000	0	30 Apr 2025	Common Stock	15,000	$0.1844	Direct	F2
transaction	INAB	Series B Warrants (right to buy)	Disposed to Issuer		-20,492	-100%		0	27 Apr 2025	Common Stock	20,492	$1.50	Direct	F2, F3, F4
transaction	INAB	Series B Warrants (right to buy)	Award		+20,492			20,492	27 Apr 2025	Common Stock	20,492	$0.4500	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025 in regards to 15,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. The remaining 5,492 warrant shares are unchanged.
F2	Fully vested and exercisable.
F3	The reported securities are included within 20,492 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.
F4	The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.